Flovid

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Flovid

Quick Facts

Property Description
Active ingredient Ofloxacin
Form Tablet, Ophthalmic solution, Otic solution
Pharmacological class Fluoroquinolone antibiotic
Common use Systemic and localized bacterial infections
Origin Synthetic compound

What is Flovid and What Class of Antibiotic is it?

Flovid is a synthetic, single-ingredient prescription medication that contains the active compound Ofloxacin. This drug is classified as a broad-spectrum antibacterial agent belonging to the fluoroquinolone antibiotic family. Ofloxacin was first approved in 1990 for use against a wide variety of bacterial pathogens.

Ofloxacin is a manufactured chemical entity, chemically defined as a quinolone carboxylic acid derivative, rather than a substance derived from natural sources. Its standing as a second-generation fluoroquinolone highlights its chemical design, intended for the elimination of bacterial infection sources, such as those affecting the urinary tract or soft tissues.

Flovid’s Mechanism and General Purpose

Flovid functions as a bactericidal agent, meaning its core mechanism is to actively kill bacterial cells. Specifically, the drug inhibits two bacterial enzymes, DNA gyrase and Topoisomerase IV, which are vital for the bacteria to maintain and copy their DNA for survival.

By disrupting this essential process—known as inhibition of bacterial DNA synthesis—the bacterial cell is prevented from multiplying and is destroyed. This targeted action underlies the drug’s general purpose: the elimination of the bacterial load causing an infection, distinguishing its action from antibiotics that only inhibit bacterial growth.

Available Forms and Administration Type

Flovid, featuring the single active ingredient Ofloxacin, is produced in various pharmaceutical preparations to enable treatment of different infection sites.

The drug is available in tablets for systemic administration (internal use) throughout the body, and in solutions, such as the ophthalmic solution and otic solution, which are formulated for topical administration to deliver the active component directly to the eyes or ears. This structural range allows Ofloxacin to reach the site where the bacterial threat is located.

Regulatory References

  1. NIH StatPearls - Ofloxacin
  2. FDA Approval 1990 (NIH StatPearls)
  3. Mechanism of Action (NIH StatPearls)

What side effects are possible with Flovid?

Possible Side Effects and Safety Information

The official safety profile of Flovid (Ofloxacin), a fluoroquinolone antibiotic, is defined by regulatory documents that classify its potential adverse reactions across various body systems and by frequency of occurrence.

Adverse reactions are formally grouped into categories such as Common (including nausea, headache, dizziness, and insomnia) and Uncommon (covering agitation, vomiting, diarrhea, and rash), based on data from clinical use and trials.

Classification Examples of Officially Documented Effects
System-Organ Class Gastrointestinal, Nervous System, Musculoskeletal and Connective Tissue Disorders, and Psychiatric Disorders.
Rare Effects Tendonitis, tendon rupture, visual disturbances, anxiety, and psychotic reactions.

The regulatory label highlights a set of Serious Adverse Reactions that are potentially disabling or irreversible. These include damage to tendons (tendon rupture, which can occur rapidly or up to several months after treatment cessation) and Peripheral Neuropathy (nerve damage in the hands or feet). Other serious documented risks involve Aortic Aneurysm and Dissection and the potential for QT Interval Prolongation on the heart's electrical rhythm.

Population-Specific Safety Notes are included for individuals at heightened risk. The official prescribing information notes that older adults (typically over 60 years of age), patients with renal impairment, or those receiving concurrent corticosteroids are at an increased risk of tendon injury. Systemic use is generally restricted in the pediatric population due to concerns regarding effects on growing joints.

Overdose and Emergency Response

Flovid Overdose and When to Seek Help

The official regulatory documents define the overdose profile for Flovid (Ofloxacin) by its documented clinical manifestations and mandated emergency response.

Overdose Scope and Manifestations

Overdose may present with specific Central Nervous System (CNS) effects, including confusion, dizziness, tremors, restlessness, and agitation, along with nausea. Regulatory texts document severe outcomes such as seizure/convulsions, loss of consciousness, and increased intracranial pressure (pseudotumor cerebri). Monitoring for potential cardiac effects, specifically QTc prolongation, is advised, especially during high-concentration exposure. Due to Ofloxacin's primary renal excretion, patients with impaired renal function are noted to be at an elevated risk of systemic accumulation and increased toxicity following overdose.

Emergency Action and Management

The regulator mandates that individuals seek immediate medical attention and contact the nearest hospital casualty/emergency department immediately upon any suspicion or manifestation of overdose. Management is strictly symptomatic and supportive, as no specific antidote is known for Ofloxacin. Procedural steps such as gastric lavage and administration of activated charcoal may be considered by medical professionals in a clinical setting. Close hospital monitoring and observation are required for all suspected overdose cases.

Therapeutic Uses of Flovid

What Flovid Treats: Main Uses and Benefits

Flovid (Ofloxacin) is a prescription antibiotic commonly used across domains where additional symptomatic support is needed, such as those involving bacterial proliferation. Ofloxacin is used in the management of various conditions, including urinary tract infections, respiratory tract infections, and skin and soft tissue infections. It is applied in contexts involving heightened systemic burden to support functional stability.

Therapeutic Domains and Symptom Relief

The medication is relevant for easing symptoms of conditions characterized by episodic or fluctuating manifestations, including UTIs, acute bacterial exacerbations of chronic bronchitis, certain bacterial conditions, and localized eye and ear infections. It is used to address symptom clusters that may become intense or disruptive, such as those involving fever, pain, purulent discharge, and compromised breathing. This supportive relief contributes to easing the overall symptom load, assisting patients during episodes of heightened discomfort and helping maintain a sense of stability when symptoms are more noticeable.

Quick Fact: Relief for Symptomatic Distress

Therapeutic Domain Symptom Types Managed Patient Benefit
Genitourinary Painful urination (dysuria), urgency, localized discomfort Helps maintain functional stability
Respiratory Persistent cough, fever, compromised breathing Contributes to easing the overall symptom load
Localized Redness, swelling, pain, purulent discharge Supports coping during difficult episodes

Regulatory References

  1. NIH StatPearls overview

Eligibility and Restrictions for Use

Flovid (Ofloxacin) eligibility is defined by regulatory agencies based on the route of administration, the patient’s age, and specific pre-existing health conditions.

Contraindicated Populations (Must Not Use)

Systemic use of Ofloxacin is formally contraindicated for patients with a known hypersensitivity to the drug or any other fluoroquinolone antibacterial agent. It must not be used by individuals with a history of epilepsy, Myasthenia Gravis, or prior tendon disorders related to the fluoroquinolone class. Furthermore, the systemic tablet form is contraindicated in children and growing adolescents.

Age and Physiological Restrictions

While systemic use is prohibited in younger patients, the topical ophthalmic and otic solutions have established safety and efficacy for specific infections in pediatric patients (e.g., as young as 6 months or 1 year, depending on the formulation). Systemic use is generally contraindicated during both pregnancy and lactation, requiring a decision to discontinue the drug or nursing.

Conditional Eligibility

Eligibility is conditional for certain populations, requiring mandatory modification or close monitoring as specified in the label. Patients with impaired renal function require a dosage reduction due to reduced drug clearance. Individuals over 60 years of age or those concurrently taking corticosteroids are at higher risk for tendon issues and require use with special caution.

What should I know about interactions with other medicines?

Flovid Interactions with other medicines and products

Flovid's official interaction profile is structured around distinct pharmacologic pathways that define co-administration constraints and monitoring requirements, as documented by regulatory authorities.

Interaction Category Specific Interacting Agent or Class
Exposure Reduction (Chelation) Metal Cations (e.g., Aluminum, Magnesium, Iron, Zinc), Antacids, Sucralfate
Pharmacodynamic Risk (Cardiac) Drugs known to prolong the QT interval (e.g., Class IA and III Antiarrhythmics, Macrolides)
Pharmacodynamic Risk (CNS) NSAIDs (Non-steroidal Anti-inflammatory Drugs), Theophylline
Altered Drug Effect (Coagulation) Warfarin and other Vitamin K Antagonists
Altered Drug Effect (Hypoglycemia) Oral Antidiabetic Agents (e.g., Glibenclamide)

Official Interaction Statements:

  • Co-administration with agents containing metal cations results in a reduction of Ofloxacin absorption, potentially decreasing its exposure.
  • Timing separation is mandated: Ofloxacin must be taken at least two hours before or two hours after metal cation-containing products.
  • The effects of oral anticoagulants like Warfarin are officially enhanced, which is associated with an increased risk of bleeding.
  • Co-use with Systemic Corticosteroids is associated with an increased risk of tendon rupture and aortic events.
  • The medicine should be used with caution alongside drugs that prolong the QT interval due to an additive risk of cardiac arrhythmia.
  • The drug's clearance is reduced in patients with impaired renal function, altering the exposure profile in that specific population.

Connection to the overall interaction profile Regulatory documents define this structure by establishing both timing constraints necessary to maintain drug exposure and mandatory monitoring requirements when co-administering with agents that amplify pharmacodynamic risks, such as those affecting coagulation or cardiac function.

Mechanism of Action

Targeted Inhibition of Bacterial Genome Maintenance

Flovid's active ingredient, Ofloxacin, functions through a bactericidal mechanism centered on the targeted inhibition of two bacterial enzymes, DNA gyrase and Topoisomerase IV, which are necessary for DNA maintenance. The drug traps these enzymes after they have cleaved the bacterial DNA, preventing the DNA strands from re-sealing. This interaction rapidly arrests the pathogen's ability to copy, transcribe, or repair its genetic material.


Cascade Leading to Pathogen Destruction

The primary consequence of this targeted enzyme inhibition is the rapid accumulation of substantial, irreversible double-strand DNA breaks. This substantial genomic damage forces the bacterial cell into a state of irreparable crisis, which triggers an apoptosis-like cell death. This mechanistic cascade results in the destruction of the bacterial cells, which constitutes the drug's bactericidal effect.


️ Mechanistic Constraints and Resistance

The effectiveness of Ofloxacin's mechanism is fundamentally constrained by bacterial defense systems, primarily efflux pumps that actively eject the drug from the cell and mutations in the target genes (gyrA and parC). These constraints limit the drug's ability to reach the necessary inhibitory concentration at the internal enzymes, which reduces the effective inhibition of the target enzymes.

Dosage and Administration Information

How to Use Flovid: Administration Guidelines

The following instructions detail the proper use of Flovid (Ofloxacin), describing the established method and timing for the medicine.

Administration Scope

Field Instruction
Route of Administration Flovid is used via Oral administration (Tablet) and Intravenous (IV) Infusion (Solution).
Standard Dosing Schedule The standard frequency for Flovid is typically twice daily (q12hr), with doses commonly ranging from 200 mg to 400 mg.
Timing Relative to Meals Flovid tablets may be taken with or without food.
Preparation Requirements The IV form is administered by a healthcare professional as a slow IV infusion over a period of 60 minutes.
Population-Specific Rules Dose adjustments are utilized for patients with reduced kidney function (creatinine clearance less than 50 mL/min). Geriatric patients may require monitoring due to age-related changes in renal function.
Missed Dose Rules If a dose is missed, it is typically taken as soon as possible unless the next dose is almost due; in that case, the missed dose is skipped and the normal schedule is resumed. Double doses are not taken.

Special Procedural Conditions

For optimal absorption and effectiveness, the oral tablet is to be swallowed whole and is not consumed with dairy products (such as milk or yogurt) or calcium-fortified juices at the same time as the medicine. The full prescribed course duration is completed, even if symptoms improve early. The duration is specific to the type of infection being addressed, ranging from a few days up to six weeks.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Flovid (Ofloxacin)


Evidence for Use in Urinary Tract Infections (UTIs)

Official research for Flovid's tablet form was studied for use against bacterial infections in the urinary tract, including both cases considered uncomplicated and more complex cases. Randomized controlled trials (RCTs) and systematic reviews have been observed in the evidence base. These studies typically monitored outcomes related to physical discomfort, such as the resolution of UTI symptoms, alongside laboratory outcomes related to clearing the bacteria from the body, known as bacteriological cure.

Flovid was observed in trials that compared its short-term measured outcomes against those of other antibiotic agents. The findings describe patterns observed in the studies where certain short-course Flovid regimens reported specified clinical and microbiological outcomes. However, it is important to note that many of these studies were conducted during periods of increased symptom activity and typically focused on immediate short-term outcomes.

Certainty remains low for using Flovid as a first-choice agent in many uncomplicated UTIs today. Evidence quality varies across studies, and regulatory bodies have noted concerns regarding the increasing rate of bacterial resistance to this class of antibiotics.


Evidence for Localized Infections (Eyes and Ears)

Research for the specialized liquid forms of Flovid—the ophthalmic (eye) and otic (ear) solutions—focuses on delivering the agent directly to the site of infection. Controlled clinical studies explored the use of the topical solution in patients with conditions like bacterial conjunctivitis and certain middle ear infections. These trials examined outcomes related to physical discomfort, such as the cessation of ear discharge (otorrhea) or the clearing of eye redness and discharge.

Findings indicate that when Flovid was observed in these localized settings, specific clinical resolution rates were reported across the studied populations. For the ear infection research, studies monitored both children and adults with conditions associated with acute or disruptive episodes. Long-term effects are not fully established, and the research for the topical solution is distinct from the research supporting the oral tablet; results apply only to the populations studied using the local application method.


Evidence in Special Populations

Research examined Flovid's use in certain special groups, including older adults and children, but generally for the specific infections where the drug is approved. For children, the evidence is limited primarily to the topical otic solution was studied for use in middle ear issues in pediatric patients, or the ophthalmic solution for bacterial eye infections. Data for certain groups remain insufficient regarding efficacy and safety beyond the approved indication use.


Long-Term Research and Follow-up Durations

The majority of pivotal clinical trials for antibiotics are designed to explore short-term symptom changes. Therefore, the follow-up durations were limited, typically lasting only a few days to a few weeks after the completion of treatment. This allows researchers to monitor responses over defined time intervals and short-term recurrence. The research provides context but not individual predictions regarding the durability of response over many months or years.


Evidence Gaps and Areas of Uncertainty

The evidence supporting Flovid's use contains acknowledged limitations. Evidence quality varies across studies, and certainty remains low for some clinical scenarios as microbial resistance patterns continually evolve. Subgroup findings are uncertain, meaning there is often limited information to precisely understand how a patient with multiple underlying health conditions might respond. The research provides context but not individual predictions.

Key Studies & References

  1. Public Assessment Report Scientific discussion Ofloxacine Stulln Unit Dose 1.5 mg/0.5 ml, ear drops, solution (ofloxacin) - Clinical Efficacy
  2. Ofloxacin - StatPearls - Indications, Adverse Effects, and Clinical Evidence Summary
  3. Review of risk minimisation for disabling and potentially long-lasting/irreversible side effects associated with fluoroquinolone antibiotics (Regulatory Context)

Frequently Asked Questions (FAQ)

Common questions about Flovid (FAQ)

Q: How quickly does Flovid typically start to work?

According to official product information, the highest concentrations of the drug in the bloodstream are typically reached about one to two hours after taking an oral dose. This timeframe describes when the medicine is fully available in the body to begin its action.


Q: Does Flovid have known interactions with herbal supplements like St. John's Wort?

Official documents state that Flovid may interact with substances containing metal cations such as iron or zinc, which are often found in vitamins and herbal supplements. Regulatory agencies emphasize the importance of patients informing their healthcare provider about all supplements being used.


Q: Does taking Flovid affect the ability to drive or operate heavy machinery?

Regulatory safety information indicates that this medication can cause side effects such as dizziness and lightheadedness. Official guidance notes that individuals should refrain from activities requiring complete mental alertness until they establish their response to the medication.


Q: Is Flovid safe for people who have liver conditions?

Liver damage, known as hepatotoxicity, is noted as a potential adverse effect of this medication in official safety profiles. Patients are cautioned to monitor for signs of liver issues, which may include yellowing of the skin or eyes. The product information directs that such symptoms warrant immediate discussion with a healthcare provider.


Q: What kind of monitoring or tests might be needed while taking Flovid?

Official safety information suggests that patients using this drug for a long duration may require routine blood work checks. Additionally, the drug's presence is noted as a factor that may interfere with the accuracy of certain laboratory tests, such as urine screenings for opiates.


Q: Does Flovid cause weight changes or affect appetite?

Regulatory documents note that a decreased appetite (anorexia) is a reported, though less common, side effect of the drug. While not a primary concern, changes in appetite can sometimes be linked to other effects observed in comprehensive side effect listings.


Q: Does Flovid interact with birth control pills?

Official statements indicate that antibiotics in the same class as Flovid may theoretically reduce the effectiveness of estrogen-containing birth control pills. Official labeling suggests patients using oral contraceptives should review the need for alternative contraceptive measures with their healthcare provider during treatment.


Q: Are there any activities or lifestyle factors that should be avoided while on Flovid?

Yes, regulatory safety documents note that this drug can increase the skin's sensitivity to light, a condition known as photosensitivity. To minimize the risk of increased skin sensitivity (photosensitivity), official guidance suggests limiting sun exposure and avoiding artificial sources of UV light, such as sunlamps and tanning beds.


Q: If Flovid doesn't seem to be working, how long should a person typically wait before talking to their doctor?

The amount of time required for improvement varies depending on the infection being treated. Official product information for some localized uses, for instance, advises that if no improvement is observed after one week, further clinical guidance is necessary to confirm the original diagnosis or determine the next step in treatment.


Q: Can Flovid interact with alcohol?

Regulatory reports do not indicate a direct interaction between the active ingredient, Ofloxacin, and alcohol. The lack of direct interaction does not account for the general effect of large amounts of alcohol on the body’s recovery from an infection.


Q: Does Flovid affect blood pressure?

Official side effect listings have reported increased blood pressure (hypertension) as an effect, though it is not common. The drug may also cause high or low blood sugar, which can sometimes manifest with symptoms like a rapid heartbeat.


Q: Why are people with certain pre-existing conditions advised against taking Flovid?

Official regulatory warnings explain that the drug may have a stimulatory effect on the central nervous system. For this reason, use is contraindicated in patients with conditions like epilepsy or a history of seizures. Use in individuals with Myasthenia Gravis is contraindicated due to the potential for the drug to worsen their symptoms.


Q: Can Flovid interfere with the results of lab tests?

Yes, official documents state that this medication may cause false positive results during specific laboratory tests, notably urine screenings for opiates. Official guidance emphasizes the necessity of informing laboratory personnel that this drug is being taken before any such screening is performed.


Q: How long does the effect of one dose of Flovid usually last?

Official pharmacokinetic information describes how the drug is cleared from the body. It has a biphasic elimination, meaning the clearance occurs in two phases. After multiple oral doses, the half-life (the time it takes for the concentration to reduce by half) is approximated to be between 4 to 5 hours initially and then lengthens to 20 to 25 hours for the second phase.


Q: What should a patient do if they develop a new symptom after starting Flovid?

Regulatory warnings indicate that treatment should be discontinued immediately at the first signs of a serious adverse reaction, such as new onset of joint pain, numbness, or effects on the central nervous system. The product label states that any concerning new or unusual symptoms arising after starting the medicine should be brought to the attention of a healthcare provider.

How should Flovid be stored and disposed of?

Official Storage and Disposal Requirements

Flovid (Ofloxacin) must be stored strictly according to governmental regulatory instructions to maintain product quality. The medication must be kept at controlled room temperature, specifically between 20 C to 25 C (68 F to 77 F). It is essential to keep the product from freezing and protect it from excess heat, light, and moisture.

The medication should be stored in its original container and kept tightly closed. For solutions, care must be taken to prevent contamination of the applicator tip to preserve sterility. For safety, all forms of Flovid must be stored out of the sight and reach of children, utilizing locked safety caps.

Outdated or unused medicine must not be kept in the home. Disposal should follow established federal or local guidelines; the product is generally not to be flushed down the toilet or sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Flovid found in:

A-Z Index: